PP405 Hair Regrowth Research

Hair grows from follicles, and follicles are rebuilt in cycles by a resident population of stem cells. In pattern hair loss, many follicles do not vanish; they miniaturise and fall dormant while their stem cells remain in place. Researchers have long known the cycle is regulated by signals around the follicle; the newer finding is that the stem cell’s own metabolism — how it handles a molecule called pyruvate — is part of the switch between dormancy and activation.[1][2]

PP405 is an investigational topical small molecule built on that finding. By inhibiting the mitochondrial pyruvate carrier, it is designed — by its third-party developer — to nudge follicle stem cells toward the metabolic state associated with activation. None of this is an approved treatment, and the strongest human evidence so far is early and company-reported.[9]

In 2017, Flores and colleagues showed in Nature Cell Biology that hair-follicle stem cells are strikingly glycolytic: they produce far more lactate than neighbouring epidermal cells, lactate dehydrogenase activity is required for their activation, and deleting the mitochondrial pyruvate carrier gene (Mpc1) in mouse follicle stem cells raised lactate output and accelerated both their activation and the hair cycle. A topical small-molecule carrier inhibitor produced a comparable acceleration in animals.[2]

In 2021 the same research programme reported that inhibiting pyruvate entry into mitochondria accelerated the hair cycle even in mouse models of alopecia driven by age, repeated chemotherapy and stress, with histologically normal follicles forming in those models. The authors framed human application as a proposal for future work — preclinical evidence, not a human result.[3]

A destroyed follicle cannot be reactivated; nothing biological remains to respond. A miniaturised follicle is different: the structure persists in reduced form, its stem cells remain resident in the bulge, and the question becomes whether the follicular system is dormant rather than gone. Independent reviews of the follicle stem-cell niche describe dormancy as an actively maintained, regulated state — which is exactly what makes it research-worthy.[10]

The developer’s framing is consistent with this: bald areas of pattern-loss scalps are described as retaining dormant follicles and stem cells. That framing is plausible within published biology, and it remains a hypothesis under clinical investigation — not an established route to regrowth.[5]

Pyruvate sits at a metabolic fork. Imported into mitochondria by the mitochondrial pyruvate carrier, it feeds oxidative energy production; kept in the cytosol, it is converted to lactate. Follicle stem cells appear to exploit that fork: their activation tracks with the lactate-producing configuration. Inhibiting the carrier shifts the balance — in mice, toward activation.[2]

The WHO INN programme’s 2026 classification of PP405 (proposed name suvomipic) as a mitochondrial pyruvate carrier inhibitor fixes this mechanism class in the international naming record. A naming record is nomenclature, not evidence of effect.[9]

The human record belongs to Pelage Pharmaceuticals. Its completed Phase 2a study (NCT06393452) was a randomized, double-blind, vehicle-controlled trial in 78 adults with androgenetic alopecia. The company reports that the trial met its primary tolerability endpoint and secondary pharmacokinetic endpoint, with no detectable systemic absorption of PP405 in blood, and reports an exploratory signal: at week 8, 31% of treated men with a higher degree of hair loss showed a greater than 20% increase in hair density, versus 0% on vehicle.[4][5]

A $120M Series B financing announced on 2025-10-15 is intended to fund Phase 3 trials from 2026. Until larger controlled, peer-reviewed results exist, the human evidence remains early, subgroup-level and company-reported.[6]

These are third-party PP405 studies. They are not Pelogen™ clinical trials, involve no Pelogen™ formulation, and establish nothing about Pelogen™.